2013 Process Chemistry Therapies 
Metabolite Tales Blog
JULY 5, 2023
A multitude of macrocyclic antiviral drugs The antiviral drug simeprevir (TMC435) was approved for the treatment of chronic hepatitis C in 2013 but has since been discontinued in favour of more effective drugs. A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Balazs et al.,
Metabolite Tales Blog
JULY 5, 2023
A multitude of macrocyclic antiviral drugs The antiviral drug simeprevir (TMC435) was approved for the treatment of chronic hepatitis C in 2013 but has since been discontinued in favour of more effective drugs. A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Balazs et al.,
Expert insights. Personalized for you.
52 
Let's personalize your content